Disposition of orally administered a promising chemotherapeutic agent flavopiridol in the intestine

References

• Jäger W, Zembsch B, Wolschann P, Pittenauer E, Senderowicz AM, Sausville EA et al. (1998). Metabolism of the anticancer drug flavopiridol, a new inhibitor of cyclin dependent kinases, in rat liver. Life Sci, 62:1861–1873.
   PubMed Web of Science ®Google Scholar
• Zhai S, Senderowicz AM, Sausville EA, Figg WD. (2002). Flavopiridol, a novel cyclin-dependent kinase inhibitor, in clinical development. Ann Pharmacother, 36:905–911.
   PubMed Web of Science ®Google Scholar
• Sedlacek HH. (2001). Mechanisms of action of flavopiridol. Crit Rev Oncol Hematol, 38:139–170.
   PubMed Web of Science ®Google Scholar
• Senderowicz AM. (2002). The cell cycle as a target for cancer therapy: basic and clinical findings with the small molecule inhibitors flavopiridol and UCN-01. Oncologist, 7 Suppl 3:12–19.
   PubMed Web of Science ®Google Scholar
• Byrd JC, Lin TS, Dalton JT, Wu D, Phelps MA, Fischer B et al. (2007). Flavopiridol administered using a pharmacologically derived schedule is associated with marked clinical efficacy in refractory, genetically high-risk chronic lymphocytic leukemia. Blood, 109:399–404.
   PubMed Web of Science ®Google Scholar
• Phelps MA, Lin TS, Johnson AJ, Hurh E, Rozewski DM, Farley KL et al. (2009). Clinical response and pharmacokinetics from a phase 1 study of an active dosing schedule of flavopiridol in relapsed chronic lymphocytic leukemia. Blood, 113:2637–2645.
   PubMed Web of Science ®Google Scholar
• Byrd JC, Peterson BL, Gabrilove J, Odenike OM, Grever MR, Rai K et al. (Cancer and Leukemia Group B. (2005). Treatment of relapsed chronic lymphocytic leukemia by 72-hour continuous infusion or 1-hour bolus infusion of flavopiridol: results from Cancer and Leukemia Group B study 19805. Clin Cancer Res, 11:4176–4181.
   PubMed Web of Science ®Google Scholar
• Lin TS, Ruppert AS, Johnson AJ, Fischer B, Heerema NA, Andritsos LA et al. (2009). Phase II study of flavopiridol in relapsed chronic lymphocytic leukemia demonstrating high response rates in genetically high-risk disease. J Clin Oncol, 27:6012–6018.
   PubMed Web of Science ®Google Scholar
• El-Rayes BF, Gadgeel S, Parchment R, Lorusso P, Philip PA. (2006). A phase I study of flavopiridol and docetaxel. Invest New Drugs, 24:305–310.
   PubMed Web of Science ®Google Scholar
• Lin TS, Blum KA, Fischer DB, Mitchell SM, Ruppert AS, Porcu P et al. (2010). Flavopiridol, fludarabine, and rituximab in mantle cell lymphoma and indolent B-cell lymphoproliferative disorders. J Clin Oncol, 28:418–423.
   PubMed Web of Science ®Google Scholar
• Karp JE, Smith BD, Resar LS, Greer JM, Blackford A, Zhao M et al. (2011). Phase 1 and pharmacokinetic study of bolus-infusion flavopiridol followed by cytosine arabinoside and mitoxantrone for acute leukemias. Blood, 117:3302–3310.
   PubMed Web of Science ®Google Scholar
• Hu M. (2007). Commentary: bioavailability of flavonoids and polyphenols: call to arms. Mol Pharm, 4:803–806.
   PubMed Web of Science ®Google Scholar
• Hagenauer B, Salamon A, Thalhammer T, Kunert O, Haslinger E, Klingler P et al. (2001). In vitro glucuronidation of the cyclin-dependent kinase inhibitor flavopiridol by rat and human liver microsomes: involvement of UDP-glucuronosyltransferases 1A1 and 1A9. Drug Metab Dispos, 29:407–414.
   PubMed Web of Science ®Google Scholar
• Ramírez J, Iyer L, Journault K, Bélanger P, Innocenti F, Ratain MJ et al. (2002). In vitro characterization of hepatic flavopiridol metabolism using human liver microsomes and recombinant UGT enzymes. Pharm Res, 19:588–594.
   PubMed Web of Science ®Google Scholar
• Hu M, Chen J, Tran D, Zhu Y, Leonardo G. (1994). The Caco-2 cell monolayers as an intestinal metabolism model: metabolism of dipeptide Phe-Pro. J Drug Target, 2:79–89.
   PubMed Web of Science ®Google Scholar
• Hu M, Chen J, Zhu Y, Dantzig AH, Stratford RE Jr, Kuhfeld MT. (1994). Mechanism and kinetics of transcellular transport of a new β-lactam antibiotic loracarbef across an intestinal epithelial membrane model system (Caco-2). Pharm Res, 11:1405–1413.
   PubMed Web of Science ®Google Scholar
• Chen J, Lin H, Hu M. (2005). Absorption and metabolism of genistein and its five isoflavone analogs in the human intestinal Caco-2 model. Cancer Chemother Pharmacol, 55:159–169.
   PubMed Web of Science ®Google Scholar
• Chen J, Lin H, Hu M. (2003). Metabolism of flavonoids via enteric recycling: role of intestinal disposition. J Pharmacol Exp Ther, 304:1228–1235.
   PubMed Web of Science ®Google Scholar
• Jia X, Chen J, Lin H, Hu M. (2004). Disposition of flavonoids via enteric recycling: enzyme-transporter coupling affects metabolism of biochanin A and formononetin and excretion of their phase II conjugates. J Pharmacol Exp Ther, 310:1103–1113.
   PubMed Web of Science ®Google Scholar
• Wang SW, Chen J, Jia X, Tam VH, Hu M. (2006). Disposition of flavonoids via enteric recycling: structural effects and lack of correlations between in vitro and in situ metabolic properties. Drug Metab Dispos, 34:1837–1848.
   PubMed Web of Science ®Google Scholar
• Liu Y, Liu Y, Dai Y, Xun L, Hu M. (2003). Enteric disposition and recycling of flavonoids and ginkgo flavonoids. J Altern Complement Med, 9:631–640.
   PubMed Web of Science ®Google Scholar
• Jeong EJ, Lin H, Hu M. (2004). Disposition mechanisms of raloxifene in the human intestinal Caco-2 model. J Pharmacol Exp Ther, 310:376–385.
   PubMed Web of Science ®Google Scholar
• Zhou Q, Zheng Z, Xia B, Tang L, Lv C, Liu W et al. (2010). Use of isoform-specific UGT metabolism to determine and describe rates and profiles of glucuronidation of wogonin and oroxylin A by human liver and intestinal microsomes. Pharm Res, 27:1568–1583.
   PubMed Web of Science ®Google Scholar
• Boerner SA, Tourne ME, Kaufmann SH, Bible KC. (2001). Effect of P-glycoprotein on flavopiridol sensitivity. Br J Cancer, 84:1391–1396.
   PubMed Web of Science ®Google Scholar
• Luke JJ, D’Adamo DR, Dickson MA, Keohan ML, Carvajal RD, Maki RG et al. (2012). The cyclin-dependent kinase inhibitor flavopiridol potentiates doxorubicin efficacy in advanced sarcomas: preclinical investigations and phase I clinical trial. Clin Cancer Res, <Volume>:.
   Google Scholar
• Artursson P, Karlsson J. (1991). Correlation between oral drug absorption in humans and apparent drug permeability coefficients in human intestinal epithelial (Caco-2) cells. Biochem Biophys Res Commun, 175:880–885.
   PubMed Web of Science ®Google Scholar
• Sun H, Pang KS. (2008). Permeability, transport, and metabolism of solutes in Caco-2 cell monolayers: a theoretical study. Drug Metab Dispos, 36:102–123.
   PubMed Web of Science ®Google Scholar
• Shugarts S, Benet LZ. (2009). The role of transporters in the pharmacokinetics of orally administered drugs. Pharm Res, 26:2039–2054.
   PubMed Web of Science ®Google Scholar